Works about SEMAGLUTIDE
Results: 446
Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.
- Published in:
- Obesity (19307381), 2025, v. 33, n. 3, p. 452, doi. 10.1002/oby.24222
- By:
- Publication type:
- Article
What Does the Rise of GLP-1 Drugs Mean for Bariatric Surgery?
- Published in:
- JAMA: Journal of the American Medical Association, 2025, v. 333, n. 9, p. 743, doi. 10.1001/jama.2024.25968
- By:
- Publication type:
- Article
Patients Are Flocking to Compounded Weight-Loss Drugs, but Are They Safe?
- Published in:
- JAMA: Journal of the American Medical Association, 2025, v. 333, n. 8, p. 652, doi. 10.1001/jama.2024.27251
- By:
- Publication type:
- Article
WEGOVY® 2.4 MG (SEMAGLUTIDE): A NEW ERA IN WEIGHT MANAGEMENT AND CV RISK REDUCTION.
- Published in:
- 2025
- Publication type:
- Product Review
Effect of Semaglutide on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults With Overweight and Insulin Resistance: Protocol for an Open-Labeled Randomized Controlled Trial.
- Published in:
- JMIR Research Protocols, 2024, v. 13, p. 1, doi. 10.2196/62667
- By:
- Publication type:
- Article
Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy.
- Published in:
- International Journal of Retina & Vitreous, 2025, v. 11, n. 1, p. 1, doi. 10.1186/s40942-024-00622-9
- By:
- Publication type:
- Article
Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes.
- Published in:
- International Journal of Retina & Vitreous, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s40942-024-00620-x
- By:
- Publication type:
- Article
Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip.
- Published in:
- Contributions / Prilozi (1857-9345), 2023, v. 44, n. 1, p. 71, doi. 10.2478/prilozi-2023-0008
- By:
- Publication type:
- Article
Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial.
- Published in:
- Biomolecules (2218-273X), 2025, v. 15, n. 1, p. 46, doi. 10.3390/biom15010046
- By:
- Publication type:
- Article
Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end‐stage‐kidney‐disease.
- Published in:
- Nephrology, 2024, v. 29, n. 6, p. 371, doi. 10.1111/nep.14277
- By:
- Publication type:
- Article
Uso da semaglutida para redução do peso em pacientes obesos não diabéticos e efeitos adversos associados.
- Published in:
- RevInter, 2023, v. 16, n. 2, p. 35, doi. 10.22280/revintervol16ed2.545
- By:
- Publication type:
- Article
Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1132004
- By:
- Publication type:
- Article
Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice.
- Published in:
- Frontiers in Endocrinology, 2023, v. 14, p. 1, doi. 10.3389/fendo.2023.1095432
- By:
- Publication type:
- Article
Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).
- Published in:
- Frontiers in Endocrinology, 2023, v. 13, p. 1, doi. 10.3389/fendo.2022.1099451
- By:
- Publication type:
- Article
Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.995007
- By:
- Publication type:
- Article
Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.851035
- By:
- Publication type:
- Article
PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice.
- Published in:
- Journal of Diabetes Investigation, 2024, v. 15, n. 11, p. 1566, doi. 10.1111/jdi.14291
- By:
- Publication type:
- Article
Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data.
- Published in:
- Journal of Diabetes Investigation, 2024, v. 15, n. 11, p. 1578, doi. 10.1111/jdi.14265
- By:
- Publication type:
- Article
A real‐world disproportionality analysis of semaglutide: Post‐marketing pharmacovigilance data.
- Published in:
- Journal of Diabetes Investigation, 2024, v. 15, n. 10, p. 1422, doi. 10.1111/jdi.14229
- By:
- Publication type:
- Article
Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
- Published in:
- 2023
- Publication type:
- Correction Notice
Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
- Published in:
- Journal of Diabetes Investigation, 2023, v. 14, n. 6, p. 774, doi. 10.1111/jdi.14000
- By:
- Publication type:
- Article
Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis.
- Published in:
- Journal of Diabetes Investigation, 2022, v. 13, n. 12, p. 1971, doi. 10.1111/jdi.13905
- By:
- Publication type:
- Article
Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.
- Published in:
- Journal of Diabetes Investigation, 2022, v. 13, n. 7, p. 1161, doi. 10.1111/jdi.13773
- By:
- Publication type:
- Article
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials.
- Published in:
- Journal of Diabetes Investigation, 2022, v. 13, n. 6, p. 975, doi. 10.1111/jdi.13764
- By:
- Publication type:
- Article
Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing.
- Published in:
- Journal of Diabetes Investigation, 2021, v. 12, n. 6, p. 978, doi. 10.1111/jdi.13429
- By:
- Publication type:
- Article
Semaglutide (Ozempic<sup>®</sup>) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss.
- Published in:
- Clinical Epidemiology, 2024, v. 16, p. 307, doi. 10.2147/CLEP.S456170
- By:
- Publication type:
- Article
Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review.
- Published in:
- Clinical Epidemiology, 2022, v. 14, p. 1463, doi. 10.2147/CLEP.S391819
- By:
- Publication type:
- Article
THE EFFICACY OF USING ORAL SEMAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES AND NONALCOHOLIC FATTY LIVER DISEASE.
- Published in:
- Journal of Gastrointestinal & Liver Diseases, 2023, v. 32, p. 37
- By:
- Publication type:
- Article
In adults with obesity and knee OA, adding weekly semaglutide to diet and activity counseling reduced weight and knee pain at 68 wk.
- Published in:
- Annals of Internal Medicine, 2025, v. 178, n. 2, p. JC20, doi. 10.7326/ANNALS-24-03988-JC
- By:
- Publication type:
- Article
In HFpEF, semaglutide reduced a composite of worsening HF or CV death.
- Published in:
- Annals of Internal Medicine, 2025, v. 178, n. 1, p. JC4, doi. 10.7326/ANNALS-24-03382-JC
- By:
- Publication type:
- Article
In adults with BMI ≥27 kg/m 2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA 1c level.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 11, p. JC122, doi. 10.7326/ANNALS-24-02457-JC
- By:
- Publication type:
- Article
In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 9, p. JC98, doi. 10.7326/ANNALS-24-01579-JC
- By:
- Publication type:
- Article
The Effect of Open-Label Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People With HIV.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 6, p. 835, doi. 10.7326/M23-3354
- By:
- Publication type:
- Article
In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 5, p. JC56, doi. 10.7326/J24-0025
- By:
- Publication type:
- Article
In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
- Published in:
- Annals of Internal Medicine, 2024, v. 177, n. 3, p. JC31, doi. 10.7326/J24-0008
- By:
- Publication type:
- Article
In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.
- Published in:
- Annals of Internal Medicine, 2023, v. 176, n. 12, p. JC136, doi. 10.7326/J23-0101
- By:
- Publication type:
- Article
In type 2 diabetes, tirzepatide reduced HbA<sub>1c</sub> vs. semaglutide.
- Published in:
- 2021
- By:
- Publication type:
- journal article
In adults with overweight or obesity, continued weekly semaglutide after a 20-wk run-in improved weight loss.
- Published in:
- 2021
- By:
- Publication type:
- journal article
In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.
- Published in:
- Annals of Medicine, 2023, v. 55, n. 2, p. 1, doi. 10.1080/07853890.2023.2239830
- By:
- Publication type:
- Article
Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study.
- Published in:
- Diabetes Care, 2024, v. 47, n. 10, p. 1834, doi. 10.2337/dc24-1082
- By:
- Publication type:
- Article
Deciphering the Effects of Semaglutide Across the Glycemic Spectrum.
- Published in:
- Diabetes Care, 2024, v. 47, n. 8, p. 1322, doi. 10.2337/dci24-0057
- By:
- Publication type:
- Article
Semaglutide and Cardiovascular Outcomes by Baseline HbA<sub>1c</sub> and Change in HbA<sub>1c</sub> in People With Overweight or Obesity but Without Diabetes in SELECT.
- Published in:
- Diabetes Care, 2024, v. 47, n. 8, p. 1360, doi. 10.2337/dc24-0764
- By:
- Publication type:
- Article
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.
- Published in:
- Diabetes Care, 2024, v. 47, n. 8, p. 1350, doi. 10.2337/dc24-0491
- By:
- Publication type:
- Article
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
- Published in:
- Diabetes Care, 2024, v. 47, n. 6, p. 1056, doi. 10.2337/dc23-2356
- By:
- Publication type:
- Article
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.
- Published in:
- Diabetes Care, 2023, v. 46, n. 4, p. 801, doi. 10.2337/dc22-1889
- By:
- Publication type:
- Article
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01949-7
- By:
- Publication type:
- Article
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.
- Published in:
- Cardiovascular Diabetology, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12933-022-01585-7
- By:
- Publication type:
- Article
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
- Published in:
- 2022
- By:
- Publication type:
- Literature Review
Correction to: Response to "Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes".
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice